Cytokeratin 18 (CK18)
Price range: $237.00 through $738.00
Description
Product Description
Cytokeratin 18 (CK18) is a 45 kDa acidic intermediate filament protein. It is normally coexpressed with cytokeratin 8 and is found in most simple ductal and glandular epithelia.15 The antibody reacts with a wide variety of neoplastic tissues such as gastrointestinal tract, lung, and breast tumors;16-18 whereas tumor cells of nonepithelial origin such as glioma, melanoma and osteosarcoma are not reactive. It also does not react with stratified squamous epithelium on most squamous cell carcinoma. Studies have also shown the reduction of CK18 may be prognostic in certain cancers.19
Specifications
Specifications
| Weight | N/A |
|---|---|
| Dimensions | N/A |
| Intended Use | |
| Species Reactivity | |
| Source | |
| Clone | |
| Isotype | |
| Antigen | |
| Localization | |
| Positive Control |
Datasheets & SDS
| Download CE Marked IVD Datasheet |
| Download IVD Datasheet Without CE Mark |
| Download RUO Data Sheet |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
References
1. Lauerova L, et al. Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule. Hybridoma. 1988 Oct;7(5):495-504.
2. Shao MM, et al. Keratin expression in breast cancers. Virchows Arch. 2012 Sept;461(3):313-22.
3. Fareed KR, et al. Caspase-cleaved cytokeratin-18 and tumor regression in gastrooesophageal adenocarcinomas treated with neoadjuvant chemotherapy. World J Gastroenterol. 2012 Apr 28;18(16):1915-20.
4. Young GD, et al. Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes. Lung Cancer. 2002 May;36 (2):133-41.
5. Woelfle U, et al. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 2004 Apr 15;10(8):2670-4.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.
